Download the ESMO 2012 Abstract Book - Oxford Journals
Download the ESMO 2012 Abstract Book - Oxford Journals
Download the ESMO 2012 Abstract Book - Oxford Journals
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Annals of Oncology<br />
Results: The frequencies of ERP29 c.293AA + PTCH1 g.79755CC (95.0 vs 80.1%,<br />
P= 0.006; PA= 86%), ERP29 c.293AA + PTCH1 g.79456CC (94.9 vs 79.4%, P= 0.005;<br />
PA= 88%), ERP29 c.293AA + ZNF415 c.443GG (56.2 vs 31.6%, P= 0.01; PA= 84%)<br />
combined genotypes were more common in patients than in controls. Individuals with<br />
<strong>the</strong> referred genotypes were under a 4.3 (95%CI: 1.61-13.43), 4.3 (95%CI: 1.63-13.49),<br />
and 3.05 (95%CI: 1.29-7.53) fold increased risk for CM than o<strong>the</strong>rs. In addition, <strong>the</strong><br />
frequencies of ERP29 c.293AA + PTCH1 g.79456CC + IKBKAP p.1072CysCys (98.5 vs<br />
83.3%, P= 0.01; PA= 86%), ERP29 c.293AA + PTCH1 g.79456CC + ZNF415 c.443GG<br />
(85.7 vs 44.1%, P= 0.004; PA= 96%) combined genotypes were also higher in patients<br />
than in controls. Individuals with <strong>the</strong> referred genotypes were under a 13.5 (95%CI:<br />
2.47-252.3) and 8.05 (95%CI: 2.21-39.24) fold increased risks for CM than o<strong>the</strong>rs.<br />
Conclusions: Our data present for <strong>the</strong> first time that: 1) ERP29 c.293A > G, PTCH1<br />
g.79755C > T and g.79456C > T, IKBKAP p.Cys1072Ser, and ZNF415 c.443A > G<br />
SNPs are important inherited risk factors for CM and; 2) healthy individuals with<br />
<strong>the</strong>se SNPs should receive recommendation to avoid sunlight exposition and should<br />
be frequently evaluated by a dermatologist to perform an early diagnosis of <strong>the</strong><br />
tumor. Financial support: FAPESP and FINEP.<br />
Disclosure: All authors have declared no conflicts of interest.<br />
1120P TIME TREND INFLUENCE OF SOCIECONOMIC STATUS<br />
ON SURVIVAL, BRESLOW THICKNESS, TIME FROM ONSET<br />
OF SYMPTOMS AND SURGICAL RESECTION IN STAGE I-II<br />
PRIMARY CUTANEOUS MELANOMA<br />
M. Mandala 1 , G. Imberti 2 , D. Piazzalunga 3 , R. Labianca 1 , G. Lucisano 4 ,<br />
B. Merelli 1 , S. Mosconi 1 , L. Marchesi 2 , A. Gianatti 5 , C. Tondini 1<br />
1 Oncology and Haematology, Ospedali Riuniti di Bergamo, Bergamo, ITALY,<br />
2 Dermatology, Ospedali Riuniti Bergamo, Bergamo, ITALY, 3 Surgical Oncology,<br />
Ospedali Riuniti Bergamo, Bergamo, ITALY, 4 Epidemiology, Mario Negri Sud,<br />
Santa Maria Imbaro, ITALY, 5 Pathology, Ospedali Riuniti Bergamo, Bergamo,<br />
ITALY<br />
Objective: To investigate <strong>the</strong> time trend influence of socioeconomic status (SES) on<br />
Breslow thickness (BT) and survival in patients (pts) with stage I-II primary<br />
cutaneous melanoma (PCM).<br />
Patients and methods: Pathologic and sociodemographic characteristics of<br />
prospectively collected, consecutive pts diagnosed with PCM between November 1,<br />
1998, and July 31, 2009 were evaluated. We categorized SES into 3 levels: low<br />
(manual employees with primary education level), middle (non-manual employees<br />
with middle education level), and high (professionals, executives with tertiary<br />
education). We divided <strong>the</strong> representative years between 2000 and 2009 into three<br />
four-year (table 1). In <strong>the</strong> multilvariate analysis models <strong>the</strong> following variables were<br />
tested: SES, marital status, sex and age.<br />
Results: A total of 1274 available pts were analyzed. Overall a progressive decrease of<br />
BT was observed (table 1). In <strong>the</strong> first four year period gender and age correlated with<br />
BT and ulceration [m vs f OR (95%CI): 1.66 (1.10-1.52) and (>60 vs G, PTCH1 G.79755C > T<br />
AND PTCH1 G.79456C > T POLYMORPHISMS WITH<br />
INHERITED RISK OF CUTANEOUS MELANOMA<br />
G.A.S. Nogueira, G.J. Lourenço, C. Oliveira, J.A. Rinck-Junior, E.F.D. Costa,<br />
A.M. Moraes, C.S.P. Lima<br />
Clinical Medical, University of Campinas, Campinas, BRAZIL<br />
Background: Recently we found that SNPs alter <strong>the</strong> oropharynx carcinoma risk in<br />
tumor suppressor MCC c.*5077A > G, PTCH1 g.79755C > T, and PTCH1 g.79456C ><br />
T. This study was conducted using high-resolution large-scale DNA microarray<br />
genotyping (5.0 SNP array, Affymetrix ®), and <strong>the</strong> quantities and functions of <strong>the</strong><br />
proteins encoded by distinct alleles of <strong>the</strong> polymorphisms are being examined by our<br />
research group. Objective: We aimed to verify whe<strong>the</strong>r <strong>the</strong> different genotypes of<br />
polymorphisms in MCC c.*5077A > G, PTCH1 g.79755C > T, and PTCH1 g.79456C<br />
> T alter <strong>the</strong> CM susceptibility.<br />
Materials and methods: Genomic DNA of 149 CM patients and 153 controls was<br />
analyzed by TaqMan genotyping (Applied Biosystems®). Statistical significance of<br />
differences between groups was calculated by using chi-square (χ2) and Fisher’s exact<br />
tests. Power analysis (PA) was used to verify <strong>the</strong> effect of sample size on <strong>the</strong> results<br />
obtained in <strong>the</strong> study.<br />
Results: Samples from patients with MC and controls were in Hardy-Weinberg<br />
equilibrium for MCC and PTCH1 loci. Similar frequencies of MCC and PTCH1<br />
genotypes were observed in patients and controls. Individuals with distinct isolated<br />
genotypes of <strong>the</strong> genes were under similar risks for CM. The frequencies of <strong>the</strong><br />
combined genotypes MCC 5077AA + PTCH1 79755CC (90.4% versus 72.3%, P=<br />
0.004; PA: 99.0%), MCC 5077AA + PTCH1 79456CC (89 0% versus 71.6%, P= 0.008;<br />
PA: 98.0%), and MCC 5077AA + PTCH1 79755CC + PTCH1 79456CC (91.3% versus<br />
76.1%, P= 0.004; PA: 99.0%) were higher in patients than in controls. Individuals<br />
with <strong>the</strong>se genotypes were at 4.44 (CI95%: 1.68 – 13.17), 3.60 (CI95%: 1.45 – .87),<br />
and 4.70 (CI95%: 1.75 – 14.63)-fold increased risks for CM than o<strong>the</strong>rs, respectively.<br />
Conclusion: Our results suggest that combined MCC and PTCH1 polymorphisms<br />
are an important inherited risk factor for CM. We believe that healthy carriers with<br />
<strong>the</strong>se genotypes deserve recommendations for protecting <strong>the</strong>ir skin from <strong>the</strong> harmful<br />
effects of UV rays to prevent tumor disease and periodic follow-up with <strong>the</strong><br />
dermatologist for early tumor diagnosis. Financial support: State of São Paulo<br />
Research Foundation (FAPESP) and Research and Project Financing (FINEP)<br />
Disclosure: All authors have declared no conflicts of interest.<br />
1122P INHERITED ABNORMALITIES IN GENES THAT DURING THE<br />
APOPTOSIS PROCESS AND CUTANEOUS MELANOMA RISK<br />
C. Oliveira 1 , J.A. Rinck-Junior 1 , G.J. Lourenço 1 , M.L. Cintra 2 , A.M. Moraes 1 ,<br />
C.S.P. Lima 1<br />
1 Department of Internal Medicine, State University of Campinas, Distrito de<br />
Barão Geraldo, Campinas, São Paulo, Brazil, BRAZIL, 2 Department of<br />
Pathology, State University of Campinas, Distrito de Barão Geraldo, Campinas,<br />
São Paulo, Brazil, BRAZIL<br />
Background: P53 (guardian of <strong>the</strong> genome), MDM2 (p53 inhibitor), BCL2<br />
(anti-apoptotic) and BAX (proapoptotic) genes remove cells damaged by ultraviolet<br />
(UV) rays of sunlight and, <strong>the</strong>refore, are related to <strong>the</strong> origin of cutaneous melanoma<br />
(CM). All <strong>the</strong>se genes are polymorphic in humans. The Arg wild allele of <strong>the</strong> P53<br />
Arg72Pro polymorphism is more efficient than <strong>the</strong> variant Pro allele at inducing<br />
apoptosis. The variant G and A alleles of MDM2 T309G and <strong>the</strong> BCL2 C (-948) A<br />
polymorphisms, and <strong>the</strong> variant A allele of <strong>the</strong> BAX G(-248)A polymorphism are<br />
related to higher and lower expressions of <strong>the</strong> encoded proteins, respectively, than <strong>the</strong>ir<br />
wild T, C and G alleles. This study aimed to clarify <strong>the</strong> roles of <strong>the</strong> above-mentioned<br />
genetic polymorphisms in <strong>the</strong> risk and clinical manifestation of <strong>the</strong> tumor.<br />
Material and methods: In this case-control study, genomic DNA from peripheral<br />
blood of 150 consecutive CM patients (75 males and 75 females, 138 Caucasians and 12<br />
non-Caucasians aged 20-89 years) and 150 healthy subjects, matched by age, gender and<br />
race, was analyzed by polymerase chain reaction followed by enzymatic digestion.<br />
Results: The frequencies of <strong>the</strong> P53 ArgArg and <strong>the</strong> BCL2 AA genotypes were higher in<br />
patients than in controls (58.7% versus 44.7%, P= 0.01) and (28.0% versus 15.3%, P=<br />
0.004), respectively. Carriers of <strong>the</strong>se genotypes had a 1.86 and 2.87-fold increased risk for<br />
CM than those with <strong>the</strong> remaining genotypes, respectively. Excesses of <strong>the</strong> P53 ArgArg<br />
plus BCL2 AA and P53 ArgArg plus BAX AA were seen in patients when compared to<br />
controls (36.1% versus 16.9%, P= 0.002) and (29.5% versus 15.3%, P= 0.008). Carriers of<br />
<strong>the</strong>se genotypes had a 3.43 and 2.71-fold increased risk for CM than o<strong>the</strong>rs, respectively.<br />
Conclusions: The data suggest that P53 Arg72Pro, BCL2 C(-248)A and BAX G<br />
(-248)A polymorphisms, alone or combined, alter <strong>the</strong> risk for CM in our region. We<br />
believe that carriers of specific genotypes of <strong>the</strong> above-mentioned genes should<br />
receive additional recommendation to avoid exposition to sunlight, in addition to<br />
frequently being evaluated by a dermatologist for early disease diagnosis. Financial<br />
support: (FAPESP)<br />
Disclosure: All authors have declared no conflicts of interest.<br />
1123P BRAF-V600 AND C-KIT MUTATION ANALYSIS IN<br />
CYTOLOGYCAL SAMPLES FROM METASTATIC MELANOMA<br />
T. Labiano 1 , M.D. Lozano 1 , J.I. Echeveste 1 , M. Montañana 1 , M.F. Sanmamed 2 ,<br />
E. Castanon Alvarez 2 , N. Gómez 1 , A. Gurpide 2 , M.A. Idoate 1 , S. Martin Algarra 3<br />
1 Pathology, University of Navarra, Pamplona, SPAIN, 2 Medical Oncology, Clinica<br />
Universitaria de Navarra, Pamplona, SPAIN, 3 Medical Oncology, Clinica<br />
Universidad de Navarra, Pamplona, SPAIN<br />
Background: Vemurafenib is approved for <strong>the</strong> first-line treatment of BRAF-V600E+<br />
metastatic melanoma (MM). Also, preliminary clinical experience with imatinib in<br />
MM patients with gene amplification or activating mutations of c-KIT, have shown<br />
Volume 23 | Supplement 9 | September <strong>2012</strong> doi:10.1093/annonc/mds404 | ix365